» Articles » PMID: 20109568

Cotransplantation of Mesenchymal Stem Cells Might Prevent Death from Graft-versus-host Disease (GVHD) Without Abrogating Graft-versus-tumor Effects After HLA-mismatched Allogeneic Transplantation Following Nonmyeloablative Conditioning

Overview
Date 2010 Jan 30
PMID 20109568
Citations 98
Authors
Affiliations
Soon will be listed here.
Abstract

Recent studies have suggested that coinfusion of mesenchymal stem cells (MSCs) the day of hematopoietic cell transplantation (HCT) might promote engraftment and prevent graft-versus-host disease (GVHD) after myeloablative allogeneic HCT. This prompted us to investigate in a pilot study whether MSC infusion before HCT could allow nonmyeloablative (NMA) HCT (a transplant strategy based nearly exclusively on graft-versus-tumor effects for tumor eradication) from HLA-mismatched donors to be performed safely. Twenty patients with hematologic malignancies were given MSCs from third party unrelated donors 30-120 minutes before peripheral blood stem cells (PBSCs) from HLA-mismatched unrelated donors, after conditioning with 2 Gy total body irradiation (TBI) and fludarabine. The primary endpoint was safety, defined as a 100-day incidence of nonrelapse mortality (NRM) <35%. One patient had primary graft rejection, whereas the remaining 19 patients had sustained engraftment. The 100-day cumulative incidence of grade II-IV acute GVHD (aGVHD) was 35%, whereas 65% of the patients experienced moderate/severe chronic GVHD (cGVHD). One-year NRM (10%), relapse (30%), overall survival (OS) (80%) and progression-free survival (PFS) (60%), and 1-year incidence of death from GVHD or infection with GVHD (10%) were encouraging. These figures compare favorably with those observed in a historic group of 16 patients given HLA-mismatched PBSCs (but no MSCs) after NMA conditioning, which had a 1-year incidence of NRM of 37% (P = .02), a 1-year incidence of relapse of 25% (NS), a 1-year OS and PFS of 44% (P = .02), and 38% (P = .1), respectively, and a 1-year rate of death from GVHD or infection with GVHD of 31% (P = .04). In conclusion, our data suggest that HLA-mismatched NMA HCT with MSC coinfusion appeared to be safe.

Citing Articles

Increasing robustness of assay for immnosuppressive effect of mesenchymal stromal/stem cells: The role of inflammatory cytokine production by peripheral blood mononuclear cells.

Sawada R, Kusakawa S, Kusuhara M, Tanaka K, Miura T, Yasuda S Regen Ther. 2025; 28:321-332.

PMID: 39877252 PMC: 11773150. DOI: 10.1016/j.reth.2024.12.016.


Co-infusion of mesenchymal stromal cells to prevent GVHD after allogeneic hematopoietic cell transplantation from HLA-mismatched unrelated donors after reduced-intensity conditioning: a double-blind randomized study and literature review.

Lombardo G, Lechanteur C, Briquet A, Seidel L, Willems E, Servais S Stem Cell Res Ther. 2024; 15(1):461.

PMID: 39627816 PMC: 11613890. DOI: 10.1186/s13287-024-04064-w.


Pathophysiology and preclinical relevance of experimental graft-versus-host disease in humanized mice.

Ehx G, Ritacco C, Baron F Biomark Res. 2024; 12(1):139.

PMID: 39543777 PMC: 11566168. DOI: 10.1186/s40364-024-00684-9.


Current Approaches for the Prevention and Treatment of Acute and Chronic GVHD.

Olivieri A, Mancini G Cells. 2024; 13(18.

PMID: 39329708 PMC: 11431085. DOI: 10.3390/cells13181524.


A review of the application of mesenchymal stem cells in the field of hematopoietic stem cell transplantation.

Lin T, Yang Y, Chen X Eur J Med Res. 2023; 28(1):268.

PMID: 37550742 PMC: 10405442. DOI: 10.1186/s40001-023-01244-x.